Advanced Accelerator Applications S.A. (NASDAQ: AAAP) announced an exclusive license agreement with Johns Hopkins University in Baltimore, Maryland to develop and market PSMA-SR6, a receptor ligand of Prostate-Specific Membrane Antigen (PSMA) for clinical therapeutic and diagnostic purposes. AAA will focus on developing this treatment and its companion diagnostic for prostate cancer through novel molecular nuclear medicine techniques similar to those implemented for the development of Lutathera and Somakit. Prostate cancer affects nearly 1 in 7 men during their lifetime worldwide.
{iframe}http://www.streetinsider.com/Corporate+News/Advanced+Accelerator+Applications+(AAAP)+Enters+Exclusive+Deal+With+Johns+Hopkins+University+for+Prostate+Cancer/11207718.html{/iframe}